Karolinska Development: Enrollment completed in Modus phase II trial

Research Note

2019-01-07

13:53

Modus Therapeutics announced today that the enrollment has been completed in the ongoing trial with sevuparin in Sickle Cell Disease.

AN

AH

Arvid Necander

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.